Results 151 to 160 of about 6,491 (191)
Some of the next articles are maybe not open access.
Optimum Dosage Regimen of Palivizumab?
Therapeutic Drug Monitoring, 2002Palivizumab is a humanized, monoclonal antibody used to protect at-risk infants against respiratory syncytial virus (RSV) infection. The regular dosage scheme causes a low initial trough level and accumulation of the antibody after subsequent injections.
Zaaijer, Hans L. +2 more
openaire +3 more sources
Cost–effectiveness of palivizumab in infancy
Expert Review of Pharmacoeconomics & Outcomes Research, 2007Respiratory syncytial virus is the most common cause of bronchiolitis, a lower respiratory tract infection occurring in infancy. It is responsible for several rehospitalizations, substantial morbidity and occasional deaths in the UK every year. Palivizumab is a recombinant monoclonal antibody that has been shown to reduce hospitalizations in infected ...
Nicholas D, Embleton +2 more
openaire +2 more sources
Use of Palivizumab in Primary Practice
Pediatrics, 2012Objective: To describe the implementation of a program for the use of palivizumab in a general pediatrics office and evaluate adherence to the 2009 American Academy of Pediatrics (AAP) guidelines. Methods: Pediatricians in a large practice were ...
Keith M, Perrin, Rodolfo E, Bégué
openaire +2 more sources
Palivizumab prophylaxis in ‘late preterm’ newborns
The Journal of Maternal-Fetal & Neonatal Medicine, 2010In the last decades the preterm birth rate rose more than 20%, largely because of an increase among deliveries of 'late preterm' infants, i.e. those born at 34 to 36 weeks gestational age. Late preterm infants are more susceptible to infection by pathogens, such as respiratory syncytial virus (RSV), possibly because of the immaturity of both the ...
LANARI, MARCELLO +2 more
openaire +3 more sources
To Palivizumab or not to Palivizumab – that is the question
Paediatric Respiratory Reviews, 2013openaire +2 more sources